Table 1.

CDK7, CycH, and MAT1 expression and clinicopathologic associations

CDK7 expression (%)CycH expression (%)MAT1 expression (%)
LowHighLowHighLowHigh
Variable(0–160)(161–300)P(0–194)(195–300)P(0–179)(180–300)P
Age
 <4016 (5.9)65 (9.7)0.04259 (9.7)46 (7.6)0.3438 (8.6)40 (8.7)0.044
 41–5072 (26.8)172 (25.6)159 (26.2)167 (27.6)111 (25.2)130 (28.1)
 51–60100 (37.2)198 (29.5)198 (32.6)182 (30)158 (35.8)126 (27.3)
 >6081 (30.1)236 (30.1)192 (31.6)211 (34.8)134 (30.4)166 (35.9)
Menopausal status
 Pre100 (37.6)259 (38.9)0.39237 (39.4)238 (39.5)0.97162 (37.1)189 (41.1)0.22
 Post166 (62.4)407 (61.1)365 (60.6)365 (60.5)275 (62.9)271 (58.9)
Tumor size (cm)
 <2.0121 (44.8)326 (48.9)0.28273 (45)307 (50.6)0.051185 (42)246 (53.7)<0.001
 ≥2.0149 (55.2)341 (51.1)334 (55)300 (49.4)255 (58)212 (46.3)
Grade
 136 (13.4)98 (14.7)84 (13.9)109 (18)53 (12.1)85 (18.6)
 282 (30.5)239 (35.9)0.16174 (28.7)229 (37.9)<0.001118 (26.9)176 (38.4)<0.001
 3151 (56.1)328 (49.3)348 (57.4)266 (44)268 (61)197 (43)
LN
 Negative186 (68.9)382 (57.2)0.001382 (62.9)363 (59.8)0.26286 (65)264 (57.5)0.021
 Positive84 (31.1)286 (42.8)225 (37.1)244 (40.2)154 (35)195 (42.5)
Local recurrence
 No210 (79.2)555 (84.3)0.07501 (84.1)486 (82.5)0.48355 (81.8)376 (83.2)0.59
 Yes55 (20.8)103 (15.7)95 (15.9)103 (17.5)79 (18.2)76 (16.8)
Regional recurrence
 No212 (80)576 (77.5)0.003510 (85.6)516 (87.6)0.3351 (80.9)399 (88.3)0.002
 Yes53 (20)82 (22.5)86 (14.4)73 (12.4)83 (19.1)53 (11.7)
Distant metastasis
 No149 (55.2)417 (62.4)0.04373 (61.6)388 (64.1)0.35251 (56.9)304 (65.9)0.005
 Yes121 (44.8)251 (37.6)233 (38.4)217 (35.9)190 (43.1)157 (34.1)